As per the agreement, upon closing of the transaction, GSK will take over all the rights & responsibilities of Janssen mentioned under the current licensing agreement b/w Janssen & Arrowhead incl. any outstanding amount to be paid by Janssen to Arrowhead
Janssen & Arrowhead will receive ~$1B as up front & potential milestone-based payments for the development & commercialization of JNJ-3989 (previously ARO-HBV) plus undisclosed tiered royalties.
Janssen will oversee carrying out the JNJ-3989 clinical trials at its expense while GSK will handle all upcoming development and commercialization efforts. GSK expects to evaluate JNJ-3989 (HBV-targeted siRNA) in a sequential regimen with bepirovirsen
Ref: GSK | Image: Arrowhead
Related News:- Arrowhead Reports the First Patient Dosing of Fazirsiran in the P-III Trial (REDWOOD) for Alpha-1 Antitrypsin Deficiency Associated Liver Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
